Transcription factors as targets for cancer therapy
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. That they are the most direct and hopeful targets for treating cancer is proposed, and this is supported by the fact that there are many more human oncogenes in signalling pathways than there are oncogenic transcription factors. But how could specific transcription-factor activity be inhibited?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3 is a member of a family of seven proteins known to play critical roles in cytokine and growth factor signaling (Darnell, 2002).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Darnell, 2002
Citations
Cites
1 retracted
Aoki, N., & Matsuda, T. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0761 · Cited by 119
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Cited by
Items 201–300 of 1,001
Tang, S., Fu, J., Shankar, S., & Srivastava, R. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031067 · Cited by 105
“esis [3,4].”
Specificity landscapes of DNA binding molecules elucidate biological function
Carlson, C. D., Warren, C. L., Hauschild, K. E., Ozers, M. S., Qadir, N., Bhimsaria, D., Lee, Y., Cerrina, F., & Ansari, A. Z. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914023107 · Cited by 108
“ZFP-1 used for CSI analysis was generated using the wheat germ expression system (1).”
MethodA Small Molecule Transcriptional Activation Domain
Minter, A. R., Brennan, B. B., & Mapp, A. K. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0473889 · Cited by 99
Baek, D., Davis, C., Ewing, B., Gordon, D., & Green, P. (2007) · Genome Research · doi:10.1101/gr.5872707 · Cited by 99
Transcriptional regulation of cellular senescence
Lanigan, F., Geraghty, J. G., & Bracken, A. P. (2011) · Oncogene · doi:10.1038/onc.2011.34 · Cited by 95
Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma
Zhang, K., Wang, M. L., Tamayo, A. T., Shacham, S., Kauffman, M. G., Lee, J., Zhang, L., Ou, Z., Li, C., Sun, L., et al. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.09.002 · Cited by 109
Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression
Ivanov, V. N., Partridge, M. A., Johnson, G. E., Huang, S. X. L., Zhou, H., & Hei, T. K. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.12.012 · Cited by 113
Hu, J., & Colburn, N. H. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0070 · Cited by 98
“Together, these findings further show that transcription factors may be good therapeutic targets (50).”
BackgroundSingle Enantiomer of YK-4-279 Demonstrates Specificity in Targeting the Oncogene EWS-FLI1
Barber-Rotenberg, J. S., Selvanathan, S. P., Kong, Y., Erkizan, H. V., Snyder, T. M., Hong, S. P., Kobs, C. L., South, N. L., Summer, S., Monroe, P. J., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.454 · Cited by 103
“Unlike targeting an enzyme at the ATP binding site, development of a therapeutic target for a transcription factor requires very specific disruption of a DNA-protein or protein-protein interaction[4].”
BackgroundAdachi, M., Cui, C., Dodge, C. T., Bhayani, M. K., & Lai, S. Y. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.06.006 · Cited by 97
Quantifying transcription factor kinetics: At work or at play?
Mueller, F., Stasevich, T. J., Mazza, D., & McNally, J. G. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.833891 · Cited by 97
“…play key roles in both development (Friedman & Kaestner, 2006) and disease progression (Look, 1997), so a solid understanding of how TFs work holds great promise in the fields of cellular reprograming (Takahashi et al., 2007), gene therapy (Darnell, 2002) and drug design (Dunker & Uversky, 2010).”
BackgroundDevelopment of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Wang, X., Qiao, Y., Asangani, I. A., Ateeq, B., Poliakov, A., Cieslik, M. P., Pitchiaya, S., Chakravarthi, B. V. S. K., Cao, X., Jing, X., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.017 · Cited by 101
Silencing STATs: lessons from paramyxovirus interferon evasion
Horvath, C. M. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.02.003 · Cited by 104
“Due to their essential roles in immediate signaling events, it has been postulated that STAT transcription factors represent ideal targets for rational therapeutic intervention for these diseases [3].”
BackgroundPark, H., Kim, M., Kwon, G. T., Lim, D. Y., Yu, R., Sung, M., Lee, K. W., Daily, J. W., & Park, J. H. Y. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.20856 · Cited by 95
Transcription and Translation Inhibitors in Cancer Treatment
Laham-Karam, N., Pinto, G., Poso, A., & Kokkonen, P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00276 · Cited by 95
“Transcription Factors The idea of targeting transcription factors in cancer has been around about 20 years (Darnell, 2002).”
BackgroundLuo, Y., Zhou, H., Krueger, J. S., Kaplan, C., Liao, D., Markowitz, D., Liu, C., Chen, T., Chuang, T. H., Xiang, R., et al. (2009) · Oncogene · doi:10.1038/onc.2009.308 · Cited by 97
Wang, Y., Ma, X., Yan, S., Shen, S., Zhu, H., Gu, Y. J., Wang, H., Qin, G., & Yu, Q. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0462 · Cited by 98
“has been suggested that STAT3 acts as an oncogene (4, 19).”
BackgroundA chemical probe toolbox for dissecting the cancer epigenome
Shortt, J., Ott, C. J., Johnstone, R. W., & Bradner, J. E. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.148 · Cited by 97
Huang, Q., Zhong, Y., Dong, H., Zheng, Q., Shi, S., Zhu, K., Qu, X., Hu, W., Zhang, X., & Wang, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111922 · Cited by 91
PDIA4: The basic characteristics, functions and its potential connection with cancer
Wang, Z., Zhang, H., & Cheng, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109688 · Cited by 114
Bifidobacterium Strain-Specific Enhances the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice
Yoon, Y., Kim, G., Jeon, B., Fang, S., & Park, H. (2021) · Cancers · doi:10.3390/cancers13050957 · Cited by 99
Stat3 as a Potential Target for Cancer Immunotherapy
Kortylewski, M., & Yu, H. (2007) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211327.76266.65 · Cited by 98
“Because Jak2 is one of the many upstream activators of Stat3, directly targeting Stat3, which affects multiple oncogenic signaling pathways in both tumor cells and diverse immune subsets that can induce immune suppression, it is likely to generate more effective antitumor immune responses.(12,99) Although blocking imm…”
BackgroundChen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q., & Zhou, J. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.023 · Cited by 96
Choi, E., Nam, J., Jung, J., Cho, N., & Cho, S. (2014) · Scientific Reports · doi:10.1038/srep07162 · Cited by 97
Gao, S. P., & Bromberg, J. F. (2006) · Science's STKE · doi:10.1126/stke.3432006pe30 · Cited by 92
“Among these STATs, STAT3 stands out by its constitutive phosphorylation in the majority of human neoplasms and its capacity to induce cell transformation and tumorigenesis (1, 2).”
BackgroundInfluentialAlbertini, V., Jain, A., Vignati, S., Napoli, S., Rinaldi, A., Kwee, I., Nur‐e‐Alam, M., Bergant, J., Bertoni, F., Carbone, G. M., et al. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl063 · Cited by 98
Targeting the Jak/STAT pathway for immunosuppression
O’Shea, J. J. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.028290 · Cited by 103
Civenni, G., Malek, A., Albino, D., Garcia-Escudero, R., Napoli, S., Di Marco, S., Pinton, S., Sarti, M., Carbone, G. M., & Catapano, C. V. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0615 · Cited by 91
“Like many other transcription factors, Myc is a difficult target to address directly with conventional small-molecule drugs (25).”
BackgroundSu, X., Hu, P., Li, D., Zhao, B.-W., Niu, Z., Herget, T., Yu, P. S., & Hu, L. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01312-5 · Cited by 113
Regulation of transcription factors by nitric oxide in neurons and in neural-derived tumor cells
Contestabile, A. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.002 · Cited by 103
Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie · doi:10.1002/ange.201412070 · Cited by 91
STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy
Spitzner, M., Ebner, R., Wolff, H., Ghadimi, B., Wienands, J., & Grade, M. (2014) · Cancers · doi:10.3390/cancers6041986 · Cited by 90
“In the past decade, various strategies have been explored to develop and implement effective STAT3 inhibitors [143–145].”
BackgroundXin, H., Wang, M., Tang, W., Shen, Z., Miao, L., Wu, W., Li, C., Wang, X., Xin, X., & Zhu, Y. Z. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6315 · Cited by 89
“STAT3 is a member of the STAT family with important roles in cellular transformation, proliferation, inflammation, and metastasis of cancer (1, 6).”
Rajasingh, J., Raikwar, H. P., Muthian, G., Johnson, C., & Bright, J. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.014 · Cited by 95
Multiplexed DNA-Modified Electrodes
Slinker, J. D., Muren, N. B., Gorodetsky, A. A., & Barton, J. K. (2010) · Journal of the American Chemical Society · doi:10.1021/ja909915m · Cited by 89
Marine natural products as targeted modulators of the transcription factor NF-κB
Folmer, F., Jaspars, M., Dicato, M. A., & Diederich, M. F. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.044 · Cited by 100
Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives
Li, Y., Song, J. H., Zhou, P., Zhou, J., & Xie, S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00691 · Cited by 92
DNA-Templated Dimerization of Hairpin Polyamides
Poulin-Kerstien, A. T., & Dervan, P. B. (2003) · Journal of the American Chemical Society · doi:10.1021/ja030494a · Cited by 100
Transcription Factor Beacons for the Quantitative Detection of DNA Binding Activity
Vallée‐Bélisle, A., Bonham, A. J., Reich, N. O., Ricci, F., & Plaxco, K. W. (2011) · Journal of the American Chemical Society · doi:10.1021/ja204775k · Cited by 88
Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders
Dölle, A., Adhikari, B., Krämer, A., Weckesser, J., Berner, N., Berger, L.-M., Diebold, M., Szewczyk, M. M., Barsyte-Lovejoy, D., Arrowsmith, C. H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00146 · Cited by 79
Kong, L.-Y., Wei, J., Sharma, A. K., Barr, J., Abou-Ghazal, M. K., Fokt, I., Weinberg, J. S., Rao, G., Grimm, E. A., Priebe, W., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0618-y · Cited by 91
“Further, STAT3 is required for both transforming growth factor (TGF)- and IL-10 production by CD4+ T cells [14], factors necessary for the generation of tumor-associated Tregs.”
Núñez, L. E., Nybo, S. E., González‐Sabín, J., Pérez, M. D., Menéndez, N., Braña, A. F., Shaaban, K. A., He, M., Morís, F., Salas, J. A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300234t · Cited by 94
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
Gu, F.-M. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i34.3922 · Cited by 86
Fontaine, F., Overman, J., & François, M. (2015) · Cell Regeneration · doi:10.1186/s13619-015-0015-x · Cited by 86
“Most promising research projects are targeting amongst others BRCA1, a tumor suppressor protein involved in DNA repair; MYC/MAX heterodimerization, involved in cell proliferation and differentiation suppression; FOXM1, a transcriptional repressor involved in chromosomal segregation and genomic stability (most intensiv…”
BackgroundBirts, C. N., Nijjar, S. K., Mardle, C. A., Hoakwie, F., Duriez, P. J., Blaydes, J. P., & Tavassoli, A. (2013) · Chemical Science · doi:10.1039/c3sc50481f · Cited by 85
Ruan, M., Ji, T., Yang, W., Duan, W., Zhou, X., He, J., Zhou, J., Chen, W., & Zhang, C. (2007) · Phytotherapy Research · doi:10.1002/ptr.2340 · Cited by 85
“This means that NF-κB is a perfect target for the treatment of cancer (Darnell, 2002).”
Kawashima, T., Bao, Y. C., Minoshima, Y., Nomura, Y., Hatori, T., Hori, T., Fukagawa, T., Fukada, T., Takahashi, N., Nosaka, T., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01423-08 · Cited by 84
“STATs have a variety of functions, including antiapoptosis, proliferation, differentiation, inflammation, and development under physiological conditions, and of note, the oncogenic activities of STAT3 and STAT5 have also been demonstrated under pathological conditions (5).”
BackgroundCai, Q., Lin, J., Wei, L., Zhang, L., Wang, L., Zhan, Y., Zeng, J., Xu, W., Shen, A., Hong, Z., et al. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13056117 · Cited by 83
“Constitutive activation of STAT3, resulting in an unregulated increase in cell proliferation and reduction in cell apoptosis, is strongly correlated with the development of numerous types of cancer including CRC [12–15].”
Wang, L., Shen, Y., Song, R., Sun, Y., Xu, J., & Xu, Q. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.059105 · Cited by 87
BET Protein Inhibitor JQ1 Attenuates Myc-Amplified MCC Tumor Growth In Vivo
Shao, Q., Kannan, A., Lin, Z., Stack, B. C., Suen, J. Y., & Gao, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0305 · Cited by 92
“Like many transcriptional targets, the lack of a ligand binding domain creates an obstacle towards direct inhibition (48).”
Nam, S., Xie, J., Perkins, A., Ma, Y., Yang, F., Wu, J., Wang, Y., Xu, R.-Z., Huang, W., Horne, D. A., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.05.002 · Cited by 85
FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles
Yang, Z. P., Jiang, S., Cheng, Y., Li, T. X., Hu, W., Ma, Z., Chen, F., & Yang, Y. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017742576 · Cited by 85
Oh, G., Pae, H., Choi, B. M., Seo, E. A., Kim, D., Shin, M. K., Kim, J. D., Kim, J. B., & Chung, H. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.09.037 · Cited by 87
Lee, H., Seo, N.-J., Jeong, S., Park, Y., Jung, D., Koh, W., Lee, H.-J., Lee, E.-O., Ahn, K. S., Ahn, K. S., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr015 · Cited by 85
“Especially, signal transducer and activator of transcription (STAT) proteins have been shown to play an important role in tumor cell survival and proliferation [6].”
BackgroundA Comprehensive Nuclear Receptor Network for Breast Cancer Cells
Kittler, R., Zhou, J., Hua, S., Ma, L., Liu, Y., Pendleton, E., Cheng, C., Gerstein, M., & White, K. P. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.004 · Cited by 81
SOX11: friend or foe in tumor prevention and carcinogenesis?
Yang, Z. P., Jiang, S., Lu, C., Ji, T., Yang, W., Li, T. X., Lv, J., Hu, W., Yang, Y., & Jin, Z. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919853449 · Cited by 84
Role of epigenetics in transformation of inflammation into colorectal cancer
Yang, Z.-H., Dang, Y.-Q., & Ji, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i23.2863 · Cited by 81
Mitelman, F., Mertens, F., & Johansson, B. (2005) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20212 · Cited by 81
Rational optimization of a transcription factor activation domain inhibitor
Basu, S., Martínez-Cristóbal, P., Frigolé-Vivas, M., Pesarrodona, M., Lewis, M., Szulc, E., Bañuelos, C. A., Sánchez-Zarzalejo, C., Bielskutė, S., Zhu, J., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01159-5 · Cited by 83
“The genes encoding transcription factors (TFs) are frequently mutated or dysregulated in cancer, and TFs are coveted targets in oncology 1,2 .”
Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro
Li, W., Saud, S. M., Young, M. R., Colburn, N. H., & Hua, B. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2424-0 · Cited by 83
“Stat3 signaling is involved in cancer progression by upregulating genes promoting cell cycle progression (cyclin D1 and c-myc) and/or preventing apoptosis (Bcl-xL, Bcl-2, and Survivin) [20, 49–51].”
BackgroundWeaver, A. M., & Silva, C. M. (2007) · Breast Cancer Research · doi:10.1186/bcr1794 · Cited by 83
“Although STAT5a and STAT5b play a fundamental role in normal growth and development of the mammary gland, both proteins are overexpressed or constitutively activated in cancers, including some breast cancer tumors [4-9].”
Role of Jun and Jun kinase in resistance of cancer cells to therapy
Vasilevskaya, I. A., & O'Dwyer, P. J. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00043-8 · Cited by 82
Interplay among transcription factors Ets21c, Fos and Ftz-F1 drives JNK-mediated tumor malignancy
Külshammer, E., Mundorf, J., Kilinc, M., Frommolt, P., Wagle, P., & Uhlirova, M. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.020719 · Cited by 65
“Indeed, TFs are often functionally altered in diverse human malignancies, frequently acting as oncoproteins or tumor suppressors (Darnell, 2002).”
Block, K. M., Wang, H., Szabó, L. Z., Polaske, N. W., Henchey, L. K., Dubey, R., Kushal, S., László, C. F., Makhoul, J., Song, Z., et al. (2009) · Journal of the American Chemical Society · doi:10.1021/ja807601b · Cited by 79
Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis
Huang, C., & Xie, K. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.01.003 · Cited by 83
“Numerous aberrant activating signal transduction pathways are involved in the initiation and progression of pancreatic tumors [32–34].”
BackgroundPeptidomimetics: A Synthetic Tool for Inhibiting Protein–Protein Interactions in Cancer
Mabonga, L., & Kappo, A. P. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09831-5 · Cited by 86
“The hyperactivation of these transcription factors has been implicated in the development of cancer (Darnell 2002).”
BackgroundMasciocchi, D., Gelain, A., Villa, S., Meneghetti, F., & Barlocco, D. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.22 · Cited by 78
Identification of a human NF-κB-activating protein, TAB3
Jin, G., Klika, A., Callahan, M., Faga, B., Danzig, J., Jiang, Z., Li, X., Stark, G. R., Harrington, J., & Sherf, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307314101 · Cited by 78
Tao, J., Zhi, X., Zhang, X., Fu, M., Huang, H., Fan, Y. J., Guan, W., & Zou, C. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0253-3 · Cited by 80
Cisplatin Mimics ARF Tumor Suppressor Regulation of RelA (p65) Nuclear Factor-κB Transactivation
Campbell, K. J., Witty, J. M., Rocha, S., & Perkins, N. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2234 · Cited by 77
Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine
Luo, Y., Zhou, H., Mizutani, M., Mizutani, N., Reisfeld, R. A., & Xiang, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1033132100 · Cited by 76
Nam, S., Wen, W. X., Schroeder, A., Herrmann, A., Yu, H., Cheng, X., Merz, K., Eisenbrand, G., Li, H., Yuan, Y., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.10.013 · Cited by 75
Ryu, K., Choy, E., Yang, C., Susa, M., Hornicek, F. J., Mankin, H., & Duan, Z. (2010) · Journal of Orthopaedic Research · doi:10.1002/jor.21088 · Cited by 75
Functional Regulatory Role of STAT3 in HPV16-Mediated Cervical Carcinogenesis
Shukla, S., Mahata, S., Shishodia, G., Pandey, A., Tyagi, A., Vishnoi, K., Basir, S. F., Das, B. C., & Bharti, A. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067849 · Cited by 79
“IL-23R) or cytoplasmic protooncogenes such as K-Ras, Src and cAbl, whose products are capable of inducing STAT3 phosphorylation [50,51,52,53].”
BackgroundSulahian, R., Casey, F., Shen, J., Qian, Z., Shin, H., Ogino, S., Weir, B. A., Vázquez, F., Liu, X. S., Hahn, W. C., et al. (2013) · Oncogene · doi:10.1038/onc.2013.517 · Cited by 80
“However, TFs other than nuclear hormone receptors are notoriously difficult drug targets (5, 6).”
BackgroundTargeting oncogenic transcription factors: therapeutic implications of endogenous STAT inhibitors
Heppler, L. N., & Frank, D. A. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.10.004 · Cited by 74
“Second, STATs act at the intersection of many upstream oncogenic signals [23], suggesting that STAT-specific inhibition may prevent resistance associated with the activation of parallel signaling pathways.”
BackgroundMandal, P. K., Liao, W. S. ‐., & McMurray, J. S. (2009) · Organic Letters · doi:10.1021/ol9012662 · Cited by 74
Zhao, W., Jaganathan, S., & Turkson, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154088 · Cited by 72
Ng, P. Y., Tang, Y., Knosp, W. M., Stadler, H. S., & Shaw, J. T. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700762 · Cited by 77
Hu, A., Huang, J., Jin, X., Li, J., Tang, Y., Huang, X., Cui, H.-J., Xu, W., & Sun, G. (2015) · Europe PMC (PubMed Central) · Cited by 73
Critical role of STAT3 in melanoma metastasis through anoikis resistance
Fofaria, N. M., & Srivastava, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2251 · Cited by 76
“Phosphorylation of STAT3 causes dimerization of STAT3 followed by its nuclear translocation where it enhances the transcription of target genes[13, 19-21].”
BackgroundA TAD Further: Exogenous Control of Gene Activation
Mapp, A. K., & Ansari, A. Z. (2007) · ACS Chemical Biology · doi:10.1021/cb600463w · Cited by 82
Vilaboa, N. E., Boré, A., Martin-Saavedra, F., Bayford, M., Winfield, N., Firth‐Clark, S., Kirton, S. B., & Voellmy, R. W. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx194 · Cited by 74
“e not specifically targetable by drug-like molecules (59,60).”
BackgroundRegulation of cell signaling pathways by dietary agents for cancer prevention and treatment
Pandey, M. K., Gupta, S. C., Nabavizadeh, A., & Aggarwal, B. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.002 · Cited by 76
“The protein structure of AP-1 reveals that it contains a basic leucine zipper (bZIP) domain, which facilitates duplex formation not only among themselves but with other bZIP proteins as well [74, 75].”
InfluentialStabilized helical peptides: overview of the technologies and therapeutic promises
Estieu‐Gionnet, K., & Guichard, G. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.603723 · Cited by 77
“Several other transcription factor complexes known to be important in human cancer [135] and involving a-helical interfaces, have been targeted with stabilized peptide helices.”
BackgroundModulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer
Seville, L., Shah, N., Westwell, A. D., & Chan, W. C. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053765816 · Cited by 81
Munde, M., Wang, S., Kumar, A., Stephens, C. E., Farahat, A. A., Boykin, D. W., Wilson, W. D., & Poon, G. M. K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt955 · Cited by 68
“Fitted values from Equation (3) in Supplementary Methods.”
BackgroundDietary cocoa inhibits colitis associated cancer: a crucial involvement of the IL-6/STAT3 pathway
Saadatdoust, Z., Pandurangan, A. K., Anandasadagopan, S. K., Esa, N. M., Ismail, A., & Mustafa, M. R. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.07.024 · Cited by 70
“STAT3 is a transcription factor that can promote oncogenesis [41] and is commonly activated in cancer [42, 43] as well as in tumor-associated myeloid cells [44].”
Allosteric Inhibition of Protein−DNA Complexes by Polyamide−Intercalator Conjugates
Fechter, E. J., & Dervan, P. B. (2003) · Journal of the American Chemical Society · doi:10.1021/ja030125e · Cited by 70
Computer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 82
TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting
Herrmann, A., Cherryholmes, G. A., Schroeder, A., Phallen, J. A., Alizadeh, D., Xin, H., Wang, T., Lee, H., Lahtz, C., Swiderski, P. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1151 · Cited by 74
Nhili, R., Peixoto, P., Depauw, S., Flajollet, S., Dezitter, X., Munde, M. M., Ismail, M. A., Kumar, A., Farahat, A. A., Stephens, C. E., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks971 · Cited by 79
“However, in spite of their important cancer generation/progression roles, transcription factors have not been extensively evaluated as targets for cancer treatment strategies (1,2).”
BackgroundMicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer
Chakravarthi, B. V. S. K., Goswami, M. T., Pathi, S. S., Robinson, A. D., Cieslik, M. P., Chandrashekar, D. S., Agarwal, S., Siddiqui, J., Daignault, S. D., Carskadon, S. L., et al. (2016) · Oncogene · doi:10.1038/onc.2016.164 · Cited by 72
Long, J., Jiang, C., Liu, B., Dai, Q., Hua, R., Chen, C., Zhang, B., & Li, H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.031 · Cited by 78
The Fra-1/AP-1 Oncoprotein: From the “Undruggable” Transcription Factor to Therapeutic Targeting
Casalino, L., Talotta, F., Cimmino, A., & Verde, P. (2022) · Cancers · doi:10.3390/cancers14061480 · Cited by 76
“The oncogenic transcription factors (TFs) were originally envisaged as ideal targets for anticancer therapies [1], and encouraging preclinical/clinical results were obtained by targeting the TFs harboring binding sites for small molecules, such as the Stat3 SH2-phosphorylation domain and the hormone-binding domains of…”
BackgroundThe role of BCL6 in lymphomas and routes to therapy
Wagner, S. D., Ahearne, M. J., & Ferrigno, P. K. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08420.x · Cited by 83
“This is because their inhibition is likely to inhibit specific transcriptional programmes whereas targeting of associated proteins may have more generalized, and more toxic, effects (Darnell, 2002; Melnick et al, 2005).”
BackgroundSmall Molecule Modulators of Transcription
Arndt, H. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600285 · Cited by 68
Chan, L. L., Pineda, M. F., Heeres, J. T., Hergenrother, P. J., & Cunningham, B. T. (2008) · ACS Chemical Biology · doi:10.1021/cb800057j · Cited by 70
“Successes in modulating proteinprotein and proteinnucleic acid interactions with small molecules fall into a few classes: surface receptorligand interactions (integrins (7–9), IL-1/2 (10, 11), TNF (12)), cytoplasmic targets (iNOS (13), HIV protease (14), Bcl-2/xL (15), XIAP (16)), and transcription-related targets ( 1…”
BackgroundTriptolide Inhibits the Differentiation of Th17 cells and Suppresses Collagen‐induced Arthritis
Wang, Y., Jia, L., & Wu, C. Y. (2008) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2008.02147.x · Cited by 68
Chan, J. S. K., Sng, M. K., Teo, Z. Q., Chong, H. C., Twang, J. S., & Tan, N. S. (2017) · Oncogene · doi:10.1038/onc.2017.319 · Cited by 70
Metadata
- Authors
- Darnell, J. E.
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 740-749
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980480652
- Cited by
- 1,194
- References
- 109
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 48 · 2022: 37 · 2021: 45 · 2020: 48 · 2019: 48 · 2018: 47 · 2017: 64 · 2016: 50 · 2015: 77 · 2014: 76 · 2013: 87 · 2012: 73
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- transcription factors, cancer therapy, anticancer drug targets, oncogenes, oncogenic transcription factor, signaling pathways, transcription factor inhibition
- MeSH terms
- Antineoplastic Agents, Cytoplasm, Cytoskeletal Proteins, Humans, Ligands, Models, Biological, Mutation, Neoplasms, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Trans-Activators, NF-kappa B, Apoptosis, Zebrafish Proteins, Wnt Proteins, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.